Cardiol Therapeutics (CRDL)
(Delayed Data from NSDQ)
$2.22 USD
+0.04 (1.83%)
Updated May 21, 2024 04:00 PM ET
After-Market: $2.23 +0.01 (0.45%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth A Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CRDL 2.22 +0.04(1.83%)
Will CRDL be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for CRDL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRDL
Here's Why You May Invest in Cardiol Therapeutics (CRDL) Stock
Is it a Good Time to Invest in Aurinia Pharmaceuticals (AUPH)?
CRDL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year?
Zacks Industry Outlook Highlights Corcept Therapeutics, Aurinia Pharmaceuticals, Alpine Immune Sciences, KalVista Pharmaceuticals and Cardiol Therapeutics
5 Stocks to Buy as Drug Industry Displays Strong Fundamentals
Other News for CRDL
Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In
CRDL Stock Earnings: Cardiol Therapeutics Meets EPS for Q1 2024
Analysts Conflicted on These Healthcare Names: Cardiol Therapeutics (CRDL) and MicroPort Scientific (OtherMCRPF)
Cardiol Therapeutics Advances Heart Disease Trials
Cardiol Therapeutics Advances Heart Disease Trials